Hamid Madanchi | Bioinformatics in Lab Medicine | Editorial Board Member

Mr. Hamid Madanchi | Bioinformatics in Lab Medicine | Editorial Board Member

Assistant Professor | Semnan University of Medical Sciences | Iran

Dr. Hamid Madanchi, Ph.D., is an Assistant Professor of Pharmaceutical Biotechnology at the Semnan University of Medical Sciences and an active researcher at the Pasteur Institute of Iran. His multidisciplinary research integrates pharmaceutical biotechnology, bioinformatics, immunoinformatics, and peptide-based drug design to develop novel therapeutics and vaccines. With extensive expertise in molecular cloning, protein engineering, computational biology, and antimicrobial peptide synthesis, Dr. Madanchi’s work focuses on the discovery and rational design of bioactive peptides with anticancer, antimicrobial, and antiviral properties. His recent investigations include the development of SARS-CoV-2 fusion inhibitors, multi-epitope vaccines against emerging pathogens, and nanobiocomposite scaffolds for biomedical applications. Dr. Madanchi has authored and co-authored numerous peer-reviewed articles in high-impact journals such as Journal of Biomolecular Structure and Dynamics, Scientific Reports, Probiotics and Antimicrobial Proteins, and BMC Bioinformatics. His scientific contributions also include studies on peptide-based drug delivery systems, targeted cancer therapies, and computational vaccine design. As principal investigator on multiple national research projects, he has led efforts in epitope-based vaccine construction, antiviral peptide discovery, and bioinformatics-driven drug repurposing. Beyond research, Dr. Madanchi has played an important role in mentoring graduate students and advancing pharmaceutical biotechnology education in Iran. His ongoing work continues to bridge experimental and computational methods for the discovery of next-generation therapeutic biomolecules addressing global health challenges.

Profile: ORCID  

Featured Publications

John Lin | Research Methods in Medical Lab Science | Best Researcher Award

Dr. John Lin |  Research Methods in Medical Lab Science | Best Researcher Award

Co-CEO | Frontage Laboratories, Inc | United States

Dr. John Lin is a distinguished research scientist affiliated with Frontage Laboratories in Exton, United States. His scientific contributions span analytical chemistry, bioanalysis, and neurodegenerative disease biomarker development. With a total of 30 publications, Dr. Lin’s research has garnered 568 citations, reflecting his consistent impact in the analytical sciences. His h-index of 13 demonstrates both productivity and citation influence across multiple studies. Notably, his recent work, “Validation of an Ultra-Sensitive Method for Quantitation of Phospho-Tau 217 (pTau217) in Human Plasma, Serum, and CSF using the ALZpath pTau217 Assay on the Quanterix HD-X Platform” (Journal of Prevention of Alzheimer’s Disease,), highlights his contribution to Alzheimer’s disease diagnostics. His earlier research includes the development and validation of LC-MS/MS and LC-HRMS methods for protein and antibody–drug conjugate quantification, published in Bioanalysis and Analytical and Bioanalytical Chemistry, respectively. Over his career, Dr. Lin has collaborated with over 230 co-authors, indicating his strong engagement in interdisciplinary research networks. His pioneering work supports precision measurement in clinical and pharmaceutical sciences, particularly enhancing biomarker quantitation technologies. Dr. Lin’s research excellence continues to influence bioanalytical method development and translational applications in clinical laboratory sciences, solidifying his reputation as a leading figure in analytical biochemistry and assay validation research

Profile: Scopus 

Featured Publications